Worth reading
41Recurring
Scored from 5 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
59
¥ millions (operating profit)Wording
Definitive
How definitive the wording is.Contents of this document
Presentation materials for financial resultsFirst quarter of the fiscal year ending October 20262 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥860 million+1.3%
Operating profit¥59 million
Ordinary income¥59 million
Net income¥33 million
Gross Profit Margin59.2 %
Operating profit margin6.9 %
Results for the three months of the current quarter
Net Sales
¥860 million
Gross profit
¥509 million
Operating profit
¥59 million
Net income
¥33 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Higher revenue from management support services for orthopedic practices¥27 million
- Decline following the unusually strong order intake in the first quarter of the previous year¥-15 million
- Other factors¥-9 million
- Self-pay treatment-focused¥-3 million
- Hybrid¥25 million
- Exosome-related¥21 million
Key KPIsA metric the company considers important as a management benchmark.
- KPI 12,137 UnknownYear on year against the same period last year+155.0%
- KPI 24,747 UnknownYear on year against the same period last year+2.4%
- KPI 3254 UnknownYear on year against the same period last year-26.4%
- KPI 413 Unknown
- KPI 51,523 Unknown
| Item | Details |
|---|---|
| Document type | Presentation materials for financial results |
| Fiscal Period Covered | First quarter of the fiscal year ending October 2026 |
| Net Sales | ¥860 million (YoY +1.3%) |
| Operating profit | ¥59 million |
| Ordinary income | ¥59 million |
| Net income | ¥33 million |
| Gross Profit Margin | 59.2 % |
| Operating profit margin | 6.9 % |
| Results for the three months of the current quarter | Net Sales ¥860 million / Gross profit ¥509 million / Operating profit ¥59 million / Net income ¥33 million |
| Breakdown of Factors Affecting the Change | Factors Higher revenue from management support services for orthopedic practices / Amount ¥27 million, Factors Decline following the unusually strong order intake in the first quarter of the previous year / Amount ¥-15 million, Factors Other factors / Amount ¥-9 million, Factors Self-pay treatment-focused / Amount ¥-3 million, Factors Hybrid / Amount ¥25 million, Factors Exosome-related / Amount ¥21 million |
| Key KPIs | KPI 1 2,137 Unknown, KPI 2 4,747 Unknown, KPI 3 254 Unknown, KPI 4 13 Unknown, KPI 5 1,523 Unknown |
Items this document does not state (20)
Selling, general and administrative expensesFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planSegment resultsUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&ANew initiatives
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The increase in revenue from management support services for orthopedic practices, along with higher earnings from the self-pay medical care-focused, hybrid, and exosome-related businesses, contributed to the results. This was partly offset by a decline following the unusually strong order intake in the first quarter of the previous year.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.